| EW |
Report |
Adjusted EPS |
BEAT |
pred ~$0.77 vs. cons $0.73 |
MEDIUM |
| EW |
Report |
TAVR revenue |
BEAT |
pred ~$1.25B vs. cons ~$1.24B |
LOW |
| EW |
Report |
TMTT revenue |
BEAT |
pred ~$192M (+43%) vs. cons ~$187M (+39%) |
MEDIUM |
| EW |
Guide |
FY2026 total sales guide |
UNCHANGED |
guide ~$6.5-6.9B (9-11%) vs. cons ~$6.7B (FY2026) |
MEDIUM |
| EW |
Guide |
FY2026 adjusted EPS guide |
UNCHANGED |
guide ~$2.95-3.05 (mid ~$3.00) vs. cons ~$3.00 (FY2026) |
MEDIUM |
| EW |
Guide |
FY2026 TMTT sales guide |
BETTER |
guide raised to ~$760-790M vs. cons ~$765M (FY2026) |
MEDIUM |
| EW |
Guide |
FY2026 TAVR growth guide |
UNCHANGED |
guide ~$4.7-5.0B (7-9%) vs. cons ~$4.85B (FY2026) |
MEDIUM |
| EW |
Guide |
TAVR NCD draft memo / US share signal commentary |
UNKNOWN |
draft memo timing ~mid-2026 (now flagged by Q4 2026) vs. mkt expecting content this call; US share read TBD (H2 2026) |
LOW |
| EW |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| EW |
Return |
5-day cumulative residual |
+1.0% (FADE) |
Stock already de-risked (~11% pullback into print, flat YTD), so a Q1-style EPS beat plus a likely TMTT guide raise should drive a positive day-1 residual (~+2.5%). But management has telegraphed tougher H2 comps and is likely to hold the total-company sales/EPS ranges rather than raise the full framework again; that out-period math implies 2H deceleration and caps upward estimate revisions. Combined with unresolved NCD-memo timing and TAVR-share ambiguity, the initial pop partially fades over the week toward a smaller residual (~+1%). |
LOW |